Enovis 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Enovis reported 3rd quarter 2026 sales of $559 million, up 2% on a reported basis and 5% on an organic basis.
- Organic growth was 6% in Recon and 3% in PNR; U.S. Recon grew 5%, including 5% growth in extremities and 3% in hips and knees, while international Recon grew 8%.
- Recon extremities grew 8% organically, and PNR grew 3% organically, including 5% growth in the U.S.
- Adjusted gross margin was 60.9%, up 60 basis points, including $8 million of tariff refunds and offset by roughly $3 million of inflationary pressure from higher raw material and freight and distribution costs tied to the Middle East conflict.
- Adjusted EBITDA margin was 18.5%, up 120 basis points year over year, and adjusted earnings per share was $0.88, up 17% versus prior year.
- Free cash flow was $35 million in the quarter and $37 million year to date, up $50 million versus the prior year; net leverage ended the quarter at 2.9 times.
- The board authorized a new 200 million share repurchase program.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Enovis third quarter 2026 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Kyle Rose, VP of Investor Relations.
Please go ahead. Good morning, everyone, and thank you for joining us today for our third quarter 2026 earnings conference call.
I'm Kyle Rose, Vice President of Investor Relations. Joining me on the call this morning are Damien McDonald, Chief Executive Officer, and Ben Berry, our Chief Financial Officer. Our earnings release was issued earlier this morning and is available in the investor section of our website, enovis.com. We also posted a slide presentation to accompany today's call on our website. Both the audio and the slide presentation of this call will be archived on our website later today. During this call, we'll be making some forward-looking statements about our beliefs and estimates regarding future events and results, including statements related to our pending acquisition of eCential Robotics.
These forward-looking statements are subject to risks and uncertainties, including those set forth in the safe harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make today. The forward-looking statements speak only as of today, and we do not assume any obligation or intend to update them, except as required by law. For further details regarding any non-GAAP financial measures referenced during this call, the accompanying reconciliation information can be found in our earnings press release and in the appendix of today's slide presentation. With that, let me turn it over to Damien.
Thanks, Kyle. Good morning, everyone, and thank you for joining us today. I'll start with an overview of our third quarter results across Recon and P&R and give a short update on eCential Robotics. Ben will then walk through the financials and our outlook for the fourth quarter and the full year before we open the call for questions. In the third quarter, we delivered organic growth of 5%, with 6% organic growth in Recon and 3% in P&R. In U.S. Recon, we grew 5% organically, with extremities up 5% and hips and knees up 3%. In extremities, we're now past the anniversary of the ARG launch, and ARG continues to be a strong growth opportunity for the future. As planned, ARVIS is expanding in shoulder, and we build upon the launch that began in Q2.
Shoulder remains a healthy market, and it is where we have one of our leading share positions globally. In hips and knees, Nebula continues to drive growth, with over 80% of new instrumentation sets going to competitive users in the quarter. While we have now annualized the launch of the Nebula in the U.S., we remain in the early stages of a multi-year product cycle. I am proud to note that it is now our top-selling stem, and we have got a long runway ahead of us. We are competing and winning in both hospital and ASC settings, and the ASC continues to be a good fit for our portfolio. Internationally, Recon grew 8% organically. As we have noted the past several quarters, market dynamics in Western Europe remain challenging, and the conflict in the Middle East continues to weigh on growth. Despite these challenges, shoulder grew double digits and led the international business.
We continue to win competitive accounts outside the U.S., and I am excited to announce we completed the first ARVIS shoulder cases in Europe last month. On eCential Robotics, we announced our binding offer to acquire the company on September 1st. Since then, we have completed the works council consultation, and we expect the deal to close by the end of the year. Integration planning is well underway. Our Recon team is working with the eCential team in Grenoble on the knee and shoulder programs, and the timelines we laid out are unchanged. In fact, through our integration planning, we are making investments to secure the talent and technology required to accelerate our development upon deal close. We expect to bring the knee robot to market within two years and shoulder to follow soon thereafter. Since the announcement, I have spent a lot of time discussing robots with surgeons.
What I hear most is how much opportunity there is to develop innovative enabling technology and implant systems which solve known problems and anticipate the evolution of surgical workflows and patient outcomes. This is an exciting inflection point for our Recon business, and we believe it will be a meaningful contributor to our sustained above-market growth. Now moving to P&R, which grew 3% organically, including 5% organic growth in the U.S. Global bracing grew 3%, driven by business mix and new products in spine, core knees, and lower extremity bracing segments. Recovery Sciences was driven by double-digit growth in Regen as we accelerate the launch of Manafuse and capitalize on key competitive conversions. Now I will turn it over to Ben, who will walk through the financial details.
Thanks, Damien. Hello, everyone. We reported third quarter sales of $559 million, up 2% versus prior year on a reported basis and up 5% on an organic basis. Reported growth included a 30 basis point headwind from foreign currency and a 250 basis point headwind related to the divestiture of Dr. Comfort. As a reminder, Q3 is the last quarter in which the Dr. Comfort divestiture affects our year-over-year comparison. Recon grew 6% organically, with extremities up 8% and up 5% in hip and knee. P&R grew 3% organically. The ongoing conflict in the Middle East was a 100 basis point headwind to international growth, which represents about 40 basis points to total Enovis growth in the quarter. We delivered adjusted gross margins of 60.9%, up 60 basis points, driven by mix and operational productivity.
This includes $8 million of tariff refunds, offset by roughly $3 million of inflationary pressure from higher raw material and freight and distribution costs tied to the Middle East conflict. Our teams continue to work on mitigation actions to soften the overall impact of inflation in this dynamic market. Adjusted EBITDA margin was 18.5%, up 120 basis points year over year. Our third quarter effective tax rate was 23%. Interest expense was $8 million for the quarter versus $9 million in the prior year. Overall, we posted adjusted earnings per share of $0.88, up 17% versus prior year. Free cash flow in the quarter was $35 million, bringing year-to-date free cash flow to $37 million, up $50 million versus the prior year. We remain confident in our 2026 target of greater than 25% free cash flow conversion.
I am encouraged by the strong demonstrated progress we have made on cash generation, which now gives us more flexibility as we think about capital allocation in the future. We exited the quarter with net leverage of 2.9 times, which is below the goal we set for the year. When the eCential transaction closes, leverage will step up about a half turn. While we remain committed to improving our balance sheet and paying down debt, we are also focused on continuing to make capital allocation decisions that we believe will drive long-term growth and shareholder value. To this end, today we announced that our board has authorized a new $200 million share repurchase program. We do not plan to materially waver from our leverage commitments. However, we plan to use this opportunistically and stay within a range of 2.5 to 3.5 times leverage.
We see real value in our long-term growth strategy, and share repurchases are another tool we can utilize to create shareholder value. Turning to full-year guidance, we are narrowing our revenue range to $2.32 billion-$2.35 billion. We expect organic growth to be approximately 5%, and we are increasing our adjusted EBITDA range to $428 million-$438 million. We are also raising our adjusted earnings per share range to $3.58-$3.79. As we outlined last quarter, in Q4, we expect modest acceleration in both segments, driven by ARVIS and Shoulder, continued Nebula conversions, and new products in P&R. Our outlook assumes the procedural environment we saw in the third quarter holds through year-end, with typical Q4 seasonality.
On the profit side, our updated guidance assumes an incremental $4 million investment in enabling technology R&D talent and a $1 million negative impact from currency. We continue to expect free cash flow conversion of greater than 25% in 2026. To summarize, the third quarter was in line with expectations we set in August in a market that remains dynamic. Cash generation continues to improve, and we are carrying new product momentum in both segments into the fourth quarter. Now I would like to turn it over to Kyle to start the Q&A.
Kyle? Thanks, Ben. In an effort to accommodate everyone in the Q&A session and keep things to a reasonable time, we ask that analysts limit questions to one question and one follow-up.
You are welcome to rejoin the queue, and we will fit you in if we still have time. With that, we would now like to open up the call to take your questions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
